Cross -Over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
A single dose, two treatments (Postday and Opxion), two periods, two sequences, crossover,
randomized, prospective design was chosen with a washout of 21 days between the two study
periods. Treatment groups were balanced with the same number of male healthy volunteers who
were randomly assigned to the study drug administration sequences.